D

Diffusion Pharmaceuticals Inc
NASDAQ:CRVO

Watchlist Manager
Diffusion Pharmaceuticals Inc
NASDAQ:CRVO
Watchlist
Price: 7.98 USD -8.9% Market Closed
Market Cap: 65.9m USD
Have any thoughts about
Diffusion Pharmaceuticals Inc?
Write Note

Diffusion Pharmaceuticals Inc
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Diffusion Pharmaceuticals Inc
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
D
Diffusion Pharmaceuticals Inc
NASDAQ:CRVO
Total Liabilities & Equity
$48.9m
CAGR 3-Years
6%
CAGR 5-Years
25%
CAGR 10-Years
0%
Abbvie Inc
NYSE:ABBV
Total Liabilities & Equity
$143.4B
CAGR 3-Years
-1%
CAGR 5-Years
19%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Total Liabilities & Equity
$54.5B
CAGR 3-Years
-7%
CAGR 5-Years
-2%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Total Liabilities & Equity
$90.9B
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Liabilities & Equity
$22.2B
CAGR 3-Years
21%
CAGR 5-Years
24%
CAGR 10-Years
25%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Liabilities & Equity
$37.4B
CAGR 3-Years
17%
CAGR 5-Years
22%
CAGR 10-Years
26%
No Stocks Found

Diffusion Pharmaceuticals Inc
Glance View

Market Cap
65.9m USD
Industry
Biotechnology

Diffusion Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Charlottesville, Virginia and currently employs 16 full-time employees. The company went IPO on 2016-11-09. Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development of therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed. The Company’s product candidate, Trans Sodium Crocetinate (TSC), is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. The firm is focused on the development of TSC for the treatment of hypoxia and as a platform to enhance standard-of-care treatment for conditions complicated by hypoxia with a particular near-term focus on hypoxic solid tumors. Hypoxia is associated with the pathophysiology of many acute and chronic conditions including cancers, heart attack, stroke, ARDS, skin and soft tissue diseases, neurodegenerative diseases and other intractable and difficult-to-treat conditions, further complicating treatment of the underlying condition by medical providers.

CRVO Intrinsic Value
9.55 USD
Undervaluation 16%
Intrinsic Value
Price
D

See Also

What is Diffusion Pharmaceuticals Inc's Total Liabilities & Equity?
Total Liabilities & Equity
48.9m USD

Based on the financial report for Sep 30, 2024, Diffusion Pharmaceuticals Inc's Total Liabilities & Equity amounts to 48.9m USD.

What is Diffusion Pharmaceuticals Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
0%

Over the last year, the Total Liabilities & Equity growth was 306%. The average annual Total Liabilities & Equity growth rates for Diffusion Pharmaceuticals Inc have been 6% over the past three years , 25% over the past five years .

Back to Top